PDT Partners LLC Takes Position in ADMA Biologics Inc $ADMA

Key Points

• PDT Partners LLC has made a new investment of approximately $1.48 million in ADMA Biologics by purchasing 74,414 shares of the company's stock during the first quarter.
• ADMA Biologics reported $0.15 earnings per share for the last quarter, which exceeded analyst expectations, along with a revenue of $121.98 million, reflecting a 13.8% increase year-over-year.
• Raymond James Financial has upgraded ADMA Biologics' stock rating to "strong-buy" with a new price target of $32.00, while the average consensus rating stands at "buy" with a target price of $27.67.

PDT Partners LLC purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 74,414 shares of the biotechnology company's stock, valued at approximately $1,476,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ADMA. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at $35,000. SVB Wealth LLC bought a new stake in ADMA Biologics during the 1st quarter worth approximately $35,000. Smartleaf Asset Management LLC raised its position in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,493 shares during the last quarter. Tsfg LLC bought a new stake in ADMA Biologics in the first quarter worth $51,000. Finally, Brooklyn Investment Group boosted its stake in ADMA Biologics by 28,655.6% during the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after buying an additional 2,579 shares during the period. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders sold 425,621 shares of company stock valued at $8,829,333. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Stock Down 1.1%

Shares of ADMA stock traded down $0.19 on Monday, hitting $16.68. The stock had a trading volume of 741,238 shares, compared to its average volume of 3,121,259. The company has a market cap of $3.98 billion, a PE ratio of 19.39 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average price of $17.67 and a 200 day moving average price of $18.97. ADMA Biologics Inc has a one year low of $13.50 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. During the same period in the previous year, the company posted $0.13 earnings per share. The firm's revenue was up 13.8% on a year-over-year basis. Research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.